Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Jennifer F. Tseng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1727-1600; OpenAlex author ID A5010925643. Sources: OpenAlex.

Their work

Papers
29 (first author 1, last author 18)
Trials
0
Grants
0
Labs led
2
Collaborators
81
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 3 papers · 2015: none · 2016: 6 papers · 2017: 6 papers · 2018: 5 papers · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper

Papers 29

  1. The Evaluation of Gallstone Disease in the Year Before Pancreatic Cancer Diagnosis. Co-author DOI 10.1016/j.jss.2023.06.017↗
  2. The impact of upper gastrointestinal surgical volume on short term pancreaticoduodenectomy outcomes for pancreatic adenocarcinoma in the SEER-Medicare populati… Co-author DOI 10.1016/j.hpb.2021.10.015↗
  3. Health Care Disparities and the Future of Pancreatic Cancer Care. Last author DOI 10.1016/j.soc.2021.06.012↗
  4. The Impact of Residential Segregation on Pancreatic Cancer Diagnosis, Treatment, and Mortality. Co-author DOI 10.1245/s10434-020-09218-7↗
  5. Opportunity Lost? Diagnostic Laparoscopy in Patients with Pancreatic Cancer in the National Surgical Quality Improvement Program Database. Co-author DOI 10.1007/s00268-018-4855-8↗
  6. Impact of Race, Insurance Status, and Primary Language on Presentation, Treatment, and Outcomes of Patients with Pancreatic Adenocarcinoma at a Safety-Net Hosp… Co-author DOI 10.1016/j.jamcollsurg.2019.05.027↗
  7. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  8. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.3617↗
  9. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. Last author DOI 10.1007/s11605-017-3541-8↗
  10. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. Last author DOI 10.1016/j.hpb.2017.12.004↗
  11. The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery. Last author DOI 10.1245/s10434-016-5676-3↗
  12. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Last author DOI 10.1002/cncr.30856↗
  13. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. Co-author DOI 10.1016/j.hpb.2017.06.010↗
  14. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Last author DOI 10.1016/j.surg.2016.08.040↗
  15. Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer. Last author DOI 10.1016/j.surg.2016.09.032↗
  16. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy. Last author DOI 10.1016/j.surg.2017.03.009↗
  17. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  18. A Tale of Two Cities: Reconsidering Adjuvant Radiation in Pancreatic Cancer Care. Last author DOI 10.1007/s11605-015-2951-8↗
  19. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. First author DOI 10.1016/j.clinthera.2016.03.006↗
  20. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. Last author DOI 10.1016/j.ejso.2016.07.016↗
  21. Early surgical bypass versus endoscopic stent placement in pancreatic cancer. Last author DOI 10.1016/j.hpb.2016.05.008↗
  22. Pancreatic adenocarcinoma. Last author DOI 10.1067/j.cpsurg.2016.01.001↗
  23. Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. Last author DOI 10.1200/jop.2016.016923↗
  24. Outcomes in operative management of pancreatic cancer. Last author DOI 10.1002/jso.23744↗
  25. Electronic medical record: research tool for pancreatic cancer? Last author DOI 10.1016/j.jss.2013.10.036↗
  26. Rankings versus reality in pancreatic cancer surgery: a real-world comparison. Last author DOI 10.1111/hpb.12171↗
  27. Outcomes following resection of pancreatic cancer. Last author DOI 10.1002/jso.23267↗
  28. A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma. Co-author PMID 24312684↗
  29. Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study. Last author DOI 10.1007/s11605-011-1699-z↗

Closest collaborators

The 25 strongest of 81 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susanna W.L. de Geus · 13 shared papers, 2016–2023 · strength 1.14
  2. Teviah Erik Sachs · 6 shared papers, 2018–2023 · strength 0.81
  3. Gyulnara G. Kasumova · 9 shared papers, 2016–2018 · strength 0.75
  4. Mariam F. Eskander · 9 shared papers, 2016–2018 · strength 0.64
  5. Marianna V. Papageorge · 3 shared papers, 2021–2023 · strength 0.58
  6. Mark P. Callery · 7 shared papers, 2014–2018 · strength 0.46
  7. Tara Sotsky Kent · 7 shared papers, 2014–2018 · strength 0.45
  8. Rebecca Anne Miksad · 6 shared papers, 2016–2018 · strength 0.42
  9. Lindsay A. Bliss · 6 shared papers, 2014–2017 · strength 0.41
  10. Arthur James Moser · 5 shared papers, 2014–2018 · strength 0.32
  11. Douglas B. Evans · 2 shared papers, 2016–2021 · strength 0.28
  12. Alexander L. Vahrmeijer · 3 shared papers, 2016–2018 · strength 0.22
  13. Anand Mahadevan · 3 shared papers, 2016–2017 · strength 0.19
  14. Elan R. Witkowski · 3 shared papers, 2012–2014 · strength 0.16
  15. Michael R. Poulson · 1 shared paper, 2021 · strength 0.16
  16. Barbara Aldana Blanco · 1 shared paper, 2021 · strength 0.16
  17. William Charles Conway · 1 shared paper, 2018 · strength 0.14
  18. Munizay Paracha · 1 shared paper, 2019 · strength 0.11
  19. Bas Groot Koerkamp · 2 shared papers, 2017–2018 · strength 0.11
  20. Marc G. Besselink · 2 shared papers, 2017–2018 · strength 0.11
  21. Casper H.J. van Eijck · 2 shared papers, 2017–2018 · strength 0.11
  22. Bert A. Bonsing · 2 shared papers, 2016–2017 · strength 0.10
  23. Mary Linton B. Peters · 1 shared paper, 2016 · strength 0.10
  24. Ana Babić · 2 shared papers, 2017–2018 · strength 0.10
  25. David C. Linehan · 2 shared papers, 2017–2018 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.